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Abstract: Chronic myeloid leukemia (CML) is characterized by a Philadelphia chromosome 
which contains an oncogene, bcr-abl. This oncogene encodes a tyrosine kinase which is consti-
tutively activated. Imatinib, a tyrosine kinase inhibitor (TKI), has been widely used in the treat-
ment of CML. Dasatinib and nilotinib were recently approved for the treatment of CML. Other 
TKIs, such as bosutinib, erlotinib, and sunitinib, are under study for the treatment of CML as 
well as other hematologic and solid malignancies. Skin rash has been reported as one of the 
most common side effects of the TKIs. Here we present a case of severe skin rash together 
with unusual symptoms of high fever and diarrhea induced by imatinib in a CML patient. The 
dermatologic toxicities from a variety of tyrosine kinase inhibitors are reviewed and general 
principles of management are also discussed.
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Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative disorder involving the 
clonal expansion of transformed hematopoietic progenitor cells. It is characterized 
by a reciprocal translocation between the long arms of chromosomes 9 and 22 which 
generate the Philadelphia chromosome (Ph) (Faderl et al 1999). This leads to formation 
of the Bcr-Abl oncogene which encodes the Bcr-Abl protein, leading to constitutive 
activation of the Abl tyrosine kinase (Nowell 2007). Imatinib mesylate, the ﬁ  rst selec-
tive tyrosine kinase inhibitor targeting Bcr-Abl protein, has shown clinical efﬁ  cacy 
in the treatment of CML by inducing complete remission and decreased mortality of 
CML patients. Since the approval of imatinib in 2001, dasatinib and nilotinib have 
been approved for use in imatinib-resistant or -intolerant CML cases (Madhusudan and 
Ganesan 2004; Ottmann et al 2005; Kantarjian et al 2006). Numerous other tyrosine 
kinase inhibitors (including anti-EGFRs and anti-VEGFRs) are under study for the 
treatment of hematologic and solid tumor malignancies. The most common side effects 
of these kinase inhibitors include myelosuppression, nausea, vomiting, diarrhea, and 
skin rashes (Schwab 2006). Here we report a case of severe, diffuse body rash together 
with unusual symptoms of fever and diarrhea in a patient with newly diagnosed CML 
after treatment with imatinib.
Case report
A 77-year-old female was found to have elevated white blood cell count (WBC) count 
on routine physical examination with lab tests. Her past medical history includes osteo-
porosis, Meniere’s disease, hypercholesterolemia, cholecystectomy, and appendectomy. Drug Design, Development and Therapy 2008:2 216
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She has a history of allergy to codeine and clarithromycin. 
She had normal functional status at the ﬁ  rst ofﬁ  ce visit. 
Physical examination was unremarkable with no palpable 
hepatosplenomegaly or lymphadenopathy. Her WBC count 
was 31,500/μL, hemoglobin was 12.5 gm/dL, hematocrit 
was 37.2%, and platelet count was 415,000/μL. Bone 
marrow revealed myeloid hyperplasia, and all metaphases 
had karyotype of t(9; 22) translocation. There were less than 
1% of myeloblasts and 19% promyelocytes. A diagnosis of 
CML in chronic phase was established. She was started on 
imatinib (Gleevec) 400 mg daily. 12 days after initiation of 
imatinib, she presented to the clinic complaining of profound 
malaise, progressive weight loss, high fever to 103 ºF (39 ºC), 
nausea, vomiting, and generalized skin rashes with no arthral-
gia or arthritis (Figure 1). The rashes were patchy, and papu-
lomacular in shape involving trunk and all extremities. At that 
time, WBC count was 35,700/μL with no eosinophilia. She 
was admitted to the Westchester Medical Center and con-
tinued to have high fevers. Imatinib was discontinued. 
The patient was treated with vancomycin and ceftazidime. 
All microbiologic cultures were repeatedly negative. 
Other infectious etiologies were also ruled out (including 
Lyme disease, Ehrlichiosis, and babesiosis). Fever, diar-
rhea, and rashes subsequently resolved after 4 days. At the 
outpatient evaluation one week later, the patient remained 
well with no residual symptoms. Imatinib 400 mg daily was 
resumed. Within hours of the ﬁ  rst dose, the patient experi-
enced recurrent fever, chills and similar rashes. Skin biopsy 
was not performed. Imatinib was immediately stopped and 
rash again resolved later. Her blood count at 2-week follow 
up evaluation revealed WBC 6,200, hemoglobin 10.4 and 
platelets 433,000. Bone marrow re-evaluation showed 1% 
blast and Ph+ in 14 out of 20 cells examined (70% Ph+). She 
was then enrolled in investigational studies (the result will 
be published separately) (Gontarewicz et al 2007; Paquette 
et al 2007; Tauchi et al 2007).
Discussion
The current case had grade 4 toxicity including skin rashes 
as well as high fever, vomiting, and diarrhea leading to dehy-
dration after ingestion of imatinib. DRESS syndrome (drug 
rash/reaction with eosinophilia and systemic symptoms, 
Figure 1 Skin rashes after ingestion of imatinib. The rashes were patchy and papulomacular in shape.Drug Design, Development and Therapy 2008:2 217
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drug hypersensitivity syndrome) is among the differential 
diagnosis (Sullivan and Shear 2001), even though this case 
does not have the full features of the syndrome due to the 
absence of internal organ damage (hepatitis) and eosinophilia. 
It has been shown that imatinib is responsible for grade 1–2 
skin rashes in 30% to 40% of the patients (O’Brien et al 2003; 
Druker et al 2006). Although rare vasculitis and Stevens-
Johnson syndrome have been reported in a few cases, skin 
rash associated with imatinib is generally mild, and is most 
often characterized by macropapular lesions occurring most 
prominently on the forearms, trunk, and occasionally on the 
face (Guilhot 2004). Grade 3–4 rash was seen in 2% to 5% 
of patients in 2 studies (O’Brien et al 2003; Guilhot 2004). 
Severe grade 4 toxicities including skin, GI, and high fever 
in a single patient has not been reported. Hair depigmentation 
and periorbital edema are two other cutaneous abnormalities 
associated with imatinib (Robert et al 2005).
As small molecules of tyrosine kinase inhibitors gradually 
arise as treatments for patients with CML and other malig-
nancies, the safety of these drugs becomes an important issue. 
The dermatologic side effects of dasatinib were observed in 
START A, B, C and L trials in a total of 789 patients with 
CML of all phases (Anon 2006). Lower incidence of skin 
rash (11% and 15%) was found in patients with blast crisis 
(myeloid and lymphoid, respectively), compared with 22% 
and 27% of the patients with accelerated and chronic phases 
of CML (Anon 2006). Most of these rashes were grade 
1–2. A rare presentation of painful subcutaneous nodules 
with overlying erythema (panniculitis) was described in 
two patients with chronic phase CML resistant to imatinib 
(Assouline et al 2006). In both cases, no cutaneous side 
effects were noticed during previous imatinib treatment 
(Assouline et al 2006). Nilotinib yields comparable results of 
rash occurrence with dasatinib and it is sometimes associated 
with dry skin. Another promising option for CML patients 
who are resistant to imatinib is bosutinib (SKI-606). In one 
of the clinical trials in patients with CML or ALL, grade 
1–2 rashes were noticed in 13% of the patients and grade 
3–4 rashes were found in 6% of the patients (Gambacorti-
Passerini et al 2007).
Epidermal growth factor receptor (EGFR) inhibitors, 
eg, erlotinib, geﬁ  tinib, panitumumab, are well known to 
induce dramatic skin rashes and other characteristic cutane-
ous changes such as curling of hair and eyelashes, periun-
gual paronychia, and xerosis (Agero et al 2006). Tyrosine 
kinase inhibitors, including the Bcr-Abl kinase inhibitors 
imatinib and dasatinib, generate milder and less signiﬁ  cant 
skin/cutaneous side effects. It appears that the cutaneous 
side effects of Bcr-Abl kinase inhibitors are rather different 
from those of EGFR inhibitors in terms of distribution and 
morphology (Table 1). The rash associated with erlotinib usu-
ally ranges from simple inﬂ  ammatory papules and pustules 
on the scalp, face, neck and upper trunk (previously termed 
“acne-like, acneiform”), to unusual vasculitis (Agero et al 
2006). Incidence of mild-moderate (grade 1–2) skin rash 
was reported from 59% to 82% (Hidalgo et al 2001; Segaert 
and Van Cutsen 2005; Journagan and Obadiab 2006). More 
severe forms such as hemorrhagic-necrotic type leuko-
cytoclastic vasculitis were described in two patients with 
advanced hepatocellular carcinoma and metastatic pancreatic 
cancer treated with erlotinib (Boeck et al 2007). Paronychia 
inﬂ  ammation, curly hair and eyelashes (Agero et al 2006), 
xerosis (Agero et al 2006), and frontal alopecia (Robert et al 
2005) were also frequently described.
Hand-foot syndrome (HFS), synonymous with hand-foot 
skin reaction and palmar-plantar erythrodysesthesia, is a 
distinct cutaneous manifestation associated with sorafenib, 
sunitinib, and lapatinib (Adams and Leggas 2007; Chu et al 
2007; Strumberg et al 2007). Approximately 13% and 18% 
of patients experienced grade 1–2 HFS, and 4% and 8% of 
patients experience grade 3–4 HFS during the course of 
sunitinib and sorafenib treatment, respectively (Adams and 
Leggas 2007; Strumberg et al 2007). HFS appears to occur 
more often when lapatinib and capecitabine were combined 
(Chu et al 2007). It is likely that capecitabine contributes to 
the development of HFS, which has already been shown to 
be a dose-limiting toxicity of capecitabine (Gressett et al 
2006). In addition to alopecia and splinter subungual hemor-
rhages, which are induced by both sorafenib and sunitinib 
in a subgroup of patients, sunitinib can also lead to skin 
discoloration (Robert et al 2005; Adams and Leggas 2007). 
Similar to imatinib, hair depigmentation and periorbital 
edema are also seen with sunitinib treatment (Robert et al 
2005; Adams and Leggas 2007).
Although skin rash occurs quite often during treat-
ment with tyrosine kinase inhibitors, there are insufﬁ  cient 
evidence-based data to establish guideline on the manage-
ment of this side effect. Due to their substantial clinical 
beneﬁ  t, continuation of therapy is preferred while the skin 
rash and other side effects are aggressively managed. In these 
cases, topical antiseptics, topical antibiotics (eg, 1% clinda-
mycin), and topical steroids have been used (Agero et al 2006 
Tsai et al 2006). Topical immunomodulatory agents such as 
pimecrolimus have also been used occasionally (Agero et al 
2006). In more severe situations, systemic antibiotics may 
be necessary since Staphylococcus aureus may supervene, Drug Design, Development and Therapy 2008:2 218
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causing secondary bacterial infection (Agero et al 2006). 
Oral tetracycline 250 mg 4 times daily or minocycline 
100 mg two times daily appears to be a suitable regimen 
(Agero et al 2006). Short-term systemic steroids may also be 
very useful, especially in patients with grade 3 or 4 rashes. 
The acceptable strategy is initial dose reduction or inter-
ruption, followed by either reinitiation of kinase inhibitors 
with concomitant short-term steroids therapy. It appears 
30 mg or 50 mg prednisone per day for two weeks offered 
good protection (Rule et al 2002; Assouline et al 2006). The 
prednisone can be gradually tapered off (Rule et al 2002) or 
to a maintenance dose of 5 mg per day for the duration of the 
course of treatment (Assouline et al 2006), depending on the 
likelihood of recurrence of skin rash. Another strategy, which 
has been used quite often is the reinitiation with gradual dose 
escalation to the level which can be tolerated by the patients 
(Rule et al 2002; Assouline et al 2006). However, there is 
signiﬁ  cant concern about the efﬁ  cacy of lower doses of kinase 
inhibitors. Skin rash usually disappear after discontinuation 
of tyrosine kinase inhibitor. In severe cases, it will resolve 
in a couple of days with the administration of either topical 
or systemic medications.
The development of skin rash related to EGFR tyrosine 
kinase inhibitors seems to have an important implication in 
the efﬁ  cacy of the treatment. The appearance of skin rash 
in patients with non-small cell lung cancer and pancreatic 
cancer treated with erlotinib is strongly associated with 
longer survival, and the overall survival is increased with 
the rash severity (Wacker et al 2007). This leads to the 
notion that induction of skin rash by dose escalation may 
Table 1 Incidence and management of skin rash and other cutaneous side effects associated with tyrosine kinase inhibitors
Grade 1, 2 skin rash Grade 3, 4 skin rash Other cutaneous 
abnormalities
Management
Imatinib 30%–40% rash 
(Schwab, Druker)
3%–5% (Guilhot); 
2% (Schwab); Rare 
vasculitis, Stevens-Johnson 
syndrome, toxic epidermal 
necrosis (Guilhot)
Hair repigmentation 
(Roberts); periorbital 
edema (Roberts)
Initially discontinue with or without 
topical/systemic steroids; then either 
restart imatinib with concomitant 
short-term steroids therapy, or restart 
imatinib with gradual does 
escalation (Rul)
Dasatinib 27% (START-A, Anon); 
11% (START-B, Anon); 
22% (START-C, Anon); 
15% (START-L, Anon)
Panniculitis (Painful 
subcutaneous nodules 
with overlying erythema) 
(Assouline)
Discontinue, restart with concomitant 
steroids after rash resolved 
(Assouline)
Nilotinib 27% (Schwab); 
17% (Kantarjian)
1% (5); 4% (Schwab) Dry skin
Bosutinib 13% (Gambacorti) 6% (Gambacorti)
Erlotnib 75% (package insert); 
59%–82% (Hidalgo); 
67%–79% (Segaert); 
77% (Journagan)
35%–50% (Wacker); 2.6% 
(Segaert)
Paronychia inﬂ  ammation; 
curly hair and eyelashes 
(Agero); Xerosis (Agero); 
frontal alopecia (Roberts)
Mile-mod: cont tx; severe: drying 
agents, topical antiseptics, topical 
antibiotics (clindamycin), systemic 
antibiotics (clindamycin, minocycline), 
topical steroids (tretinoin), topical 
immunomodulatory agents 
(pimecrolimus) and short term topical 
steroids or systemic steroids (Agero)
Lapatinib 26% rash; 41% HFS 
(package insert, Chu)
2% rash; 12% HFS 
(package insert, Chu)
Xerosis, pruritus, alopecia 
(package insert, Chu)
Sorafenib 18% HFS (Strumberg); 
24% rash (Strumberg)
8% HFS (Strumberg); 
2% rash (Strumberg)
18% Alopecia (Strumberg); 
splinter subungual 
hemorrhages (Roberts)
Dose reduction and interruption
Sunitinib 14% rash; 13% HFS (Adams); 
seborrheic dermatitis-like 
rash (Tsai)
1% rash (Adams); 
4% HFS (Adams)
5% alopecia; 8% hair 
depigmentation; 30% skin 
discoloration (Adams); 
periorbital edema 
(Roberts); splinter 
subungual hemorrhages 
(Roberts)
Topical 0.1% mometasone 
furoateointment and 
discontinuation of sunitinib (Tsai)
Abbreviations: Tx, therapy; HFS, hand-foot syndrome.Drug Design, Development and Therapy 2008:2 219
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correlate with higher efﬁ  cacy of tyrosine kinase inhibitors in 
the treatment of malignancies. Further understanding of the 
underlying mechanisms leading to the development of the 
rashes from different class of TKIs may assist us in ﬁ  nding 
new drug targets and modify the current therapies to a level 
of maximal efﬁ  cacy.
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